Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsDowngradesPrice Target
Citigroup analyst Geoff Meacham downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Buy to Neutral and lowers the price target from $5 to $1.
Citigroup analyst Geoff Meacham downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Buy to Neutral and lowers the price target from $5 to $1.